Tissue Factor Coagulation Pathway

A New Therapeutic Target in Atherothrombosis

Juan Viles Gonzalez, Sunil X. Anand, M. Urooj Zafar, Valentin Fuster, Juan J. Badimon

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Atherothrombosis, defined as atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of acute coronary syndromes and cardiovascular deaths. It is the leading cause of morbidity and mortality in the industrialized world. Plaque composition, rather than luminal stenosis, is recognized as the major determinant of this disease. Since tissue factor is found within atheroma and also in the bloodstream of atherosclerotic patients, it likely plays a key role in determining both plaque and blood thrombogenicity. Ongoing clinical and preclinical studies are evaluating the therapeutic possibilities of specific inhibition of the tissue factor pathway. Here, we will review the role of tissue factor in atherothrombosis and therapeutic applications.

Original languageEnglish
Pages (from-to)669-676
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume43
Issue number5
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Thromboplastin
Atherosclerotic Plaques
Acute Coronary Syndrome
Pathologic Constriction
Thrombosis
Therapeutics
Morbidity
Mortality

Keywords

  • Antithrombotics
  • Atherothrombosis
  • Factor x inhibitors
  • Thrombin inhibitors
  • Tissue factor

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Tissue Factor Coagulation Pathway : A New Therapeutic Target in Atherothrombosis. / Viles Gonzalez, Juan; Anand, Sunil X.; Zafar, M. Urooj; Fuster, Valentin; Badimon, Juan J.

In: Journal of Cardiovascular Pharmacology, Vol. 43, No. 5, 01.05.2004, p. 669-676.

Research output: Contribution to journalArticle

Viles Gonzalez, Juan ; Anand, Sunil X. ; Zafar, M. Urooj ; Fuster, Valentin ; Badimon, Juan J. / Tissue Factor Coagulation Pathway : A New Therapeutic Target in Atherothrombosis. In: Journal of Cardiovascular Pharmacology. 2004 ; Vol. 43, No. 5. pp. 669-676.
@article{4d22cf87118c47eebd26419f0e4a99e3,
title = "Tissue Factor Coagulation Pathway: A New Therapeutic Target in Atherothrombosis",
abstract = "Atherothrombosis, defined as atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of acute coronary syndromes and cardiovascular deaths. It is the leading cause of morbidity and mortality in the industrialized world. Plaque composition, rather than luminal stenosis, is recognized as the major determinant of this disease. Since tissue factor is found within atheroma and also in the bloodstream of atherosclerotic patients, it likely plays a key role in determining both plaque and blood thrombogenicity. Ongoing clinical and preclinical studies are evaluating the therapeutic possibilities of specific inhibition of the tissue factor pathway. Here, we will review the role of tissue factor in atherothrombosis and therapeutic applications.",
keywords = "Antithrombotics, Atherothrombosis, Factor x inhibitors, Thrombin inhibitors, Tissue factor",
author = "{Viles Gonzalez}, Juan and Anand, {Sunil X.} and Zafar, {M. Urooj} and Valentin Fuster and Badimon, {Juan J.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1097/00005344-200405000-00009",
language = "English",
volume = "43",
pages = "669--676",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Tissue Factor Coagulation Pathway

T2 - A New Therapeutic Target in Atherothrombosis

AU - Viles Gonzalez, Juan

AU - Anand, Sunil X.

AU - Zafar, M. Urooj

AU - Fuster, Valentin

AU - Badimon, Juan J.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Atherothrombosis, defined as atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of acute coronary syndromes and cardiovascular deaths. It is the leading cause of morbidity and mortality in the industrialized world. Plaque composition, rather than luminal stenosis, is recognized as the major determinant of this disease. Since tissue factor is found within atheroma and also in the bloodstream of atherosclerotic patients, it likely plays a key role in determining both plaque and blood thrombogenicity. Ongoing clinical and preclinical studies are evaluating the therapeutic possibilities of specific inhibition of the tissue factor pathway. Here, we will review the role of tissue factor in atherothrombosis and therapeutic applications.

AB - Atherothrombosis, defined as atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of acute coronary syndromes and cardiovascular deaths. It is the leading cause of morbidity and mortality in the industrialized world. Plaque composition, rather than luminal stenosis, is recognized as the major determinant of this disease. Since tissue factor is found within atheroma and also in the bloodstream of atherosclerotic patients, it likely plays a key role in determining both plaque and blood thrombogenicity. Ongoing clinical and preclinical studies are evaluating the therapeutic possibilities of specific inhibition of the tissue factor pathway. Here, we will review the role of tissue factor in atherothrombosis and therapeutic applications.

KW - Antithrombotics

KW - Atherothrombosis

KW - Factor x inhibitors

KW - Thrombin inhibitors

KW - Tissue factor

UR - http://www.scopus.com/inward/record.url?scp=2042449992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2042449992&partnerID=8YFLogxK

U2 - 10.1097/00005344-200405000-00009

DO - 10.1097/00005344-200405000-00009

M3 - Article

VL - 43

SP - 669

EP - 676

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 5

ER -